239 related articles for article (PubMed ID: 23225005)
1. Mechanisms of transthyretin aggregation and toxicity.
Gasperini RJ; Klaver DW; Hou X; Aguilar MI; Small DH
Subcell Biochem; 2012; 65():211-24. PubMed ID: 23225005
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
3. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
4. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
Cardoso I; Saraiva MJ
FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
[TBL] [Abstract][Full Text] [Related]
5. Familial amyloidotic polyneuropathy and transthyretin.
Nagasaka T
Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
[TBL] [Abstract][Full Text] [Related]
6. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
7. Relationship between amyloid deposition and intracellular structural changes in familial amyloidotic polyneuropathy.
Misumi Y; Ueda M; Obayashi K; Jono H; Su Y; Yamashita T; Ohshima T; Ando Y; Uchino M
Hum Pathol; 2012 Jan; 43(1):96-104. PubMed ID: 21777941
[TBL] [Abstract][Full Text] [Related]
8. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
[TBL] [Abstract][Full Text] [Related]
9. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
10. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.
Schmidt M; Wiese S; Adak V; Engler J; Agarwal S; Fritz G; Westermark P; Zacharias M; Fändrich M
Nat Commun; 2019 Nov; 10(1):5008. PubMed ID: 31676763
[TBL] [Abstract][Full Text] [Related]
11. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
12. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.
Bergström J; Gustavsson A; Hellman U; Sletten K; Murphy CL; Weiss DT; Solomon A; Olofsson BO; Westermark P
J Pathol; 2005 Jun; 206(2):224-32. PubMed ID: 15810051
[TBL] [Abstract][Full Text] [Related]
13. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
14. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
15. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin deposition in familial amyloidotic polyneuropathy.
Saraiva MJ; Magalhaes J; Ferreira N; Almeida MR
Curr Med Chem; 2012; 19(15):2304-11. PubMed ID: 22471982
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration.
Hou X; Aguilar MI; Small DH
FEBS J; 2007 Apr; 274(7):1637-50. PubMed ID: 17381508
[TBL] [Abstract][Full Text] [Related]
18. Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy.
Magalhães J; Saraiva MJ
J Neuropathol Exp Neurol; 2011 Dec; 70(12):1097-106. PubMed ID: 22082661
[TBL] [Abstract][Full Text] [Related]
19. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
20. Potential use of glucuronylglucosyl-β-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy.
Jono H; Anno T; Motoyama K; Misumi Y; Tasaki M; Oshima T; Mori Y; Mizuguchi M; Ueda M; Shinriki S; Shono M; Obayashi K; Arima H; Ando Y
Amyloid; 2012 Jun; 19 Suppl 1():50-2. PubMed ID: 22620966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]